GlaxoSmithKline’s new chief executive said on Tuesday that the British drugmaker would have a look at Pfizer Inc’s consumer products business, but would not overpay for the asset.
Pfizer, the largest U.S. drugmaker, said last year it was considering strategic alternatives, including a sale or spinoff, of the consumer business, which had sales of about $3.4 billion in 2016 and could cost more than $15 billion to acquire.
“At this stage it would be weird if we didn’t look at it,” GSK Chief Executive Emma Walmsley said, responding to questions at the JP Morgan Healthcare Conference in San Francisco.
But she said it is only a look and very early, adding, “we don’t need it and we won’t overpay for it.”
Despite her consumer products background, Walmsley repeatedly said that the company’s pharmaceuticals business and pharma research and development is GSK’s top priority.
However, Walmsley said GSK has a good track record of integrating large acquisitions and that it’s consumer business does have room to grow.
Pfizer’s consumer portfolio includes well-known brands such as Advil, Chapstick lip balm and Centrum vitamins.
Walmsley said there are a very small number of assets that would be completely complementary to GSK’s existing consumer business, “and this may be one of them.”
“If we did it, it is cash generating,” she said.
By Bill Berkrot
Source: Reuters
According to a study conducted by the company that included more than 600 participants, samples collected with the Teal Wand were shown to be just as accurate as those taken by a clinician during an office visit. About 94% of participants said they would opt for self-collection in the future, and 86% said they felt they would be more likely to stay up to date with cervical cancer screening if they could do it at home.
Jeremy Walsh was named head of IT and AI, according to his post on LinkedIn. The move was first reported by Politico. Walsh previously held the role of chief technologist at Booz Allen Hamilton, managing AI- and cloud-based projects for 14 years at the consultancy.
The new organization features two Business Groups that will rely on dedicated teams and assets to fully focus on meeting customer and market needs. Isabelle Bouvier is appointed as CEO of the Health & Pharma Solutions Business Group and Pascal Leroy as CEO of the Nutrition & Bioindustry Business Group. Béatrice Totel replaces Isabelle Bouvier as CFO of Roquette.
